Case report

Toxic ‘Toxo’ in the heart: Cardiac toxoplasmosis following a hematopoietic stem cell transplant- a case report

Padmastuti Akella*, Isha Bhatt, Mustapha Serhan, Dilip D. Giri, Stephen M. Pastores

Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, United States

A R T I C L E   I N F O

Article history:
Received 8 June 2021
Accepted 3 July 2021

Keywords:
Toxoplasmosis
Cardiac
Hematopoietic stem cell transplant
Parasitic infection
Autopsy
PCR
Myocarditis

A B S T R A C T

Toxoplasmosis is a rare but potentially severe complication after allogeneic hematopoietic cell transplantation. Toxoplasma gondii-associated cardiac involvement can cause myocarditis, pericarditis, arrhythmias, and congestive heart failure. Most cases with cardiac toxoplasmosis following BMT have been fatal and diagnosed at autopsy. We present an unfortunate case of sudden onset congestive heart failure symptoms and delayed post-transplant Toxoplasma PCR testing that ultimately led to the diagnosis of cardiac toxoplasmosis on autopsy in our patient.

© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Toxoplasmosis is a life-threatening parasitic infection that can affect hematopoietic stem cell (HSCT) and solid organ transplant recipients [1–3]. In HSCT recipients, the major risk of toxoplasmosis results from the reactivation of a pre-transplant latent infection with Toxoplasma gondii in seropositive recipients. Cardiac involvement in toxoplasmosis is very uncommon and can manifest with myocarditis, pericardial effusion, constricitive pericarditis, arrhythmias, and congestive heart failure [1,3]. We present an uncommon and unique case of cardiac toxoplasmosis following allogeneic HSCT causing acute decompensated heart failure leading to multisystem organ failure and death.

Case description

A 69-year-old man with history of chronic kidney disease, hypothyroidism, atrial fibrillation and follicular lymphoma was admitted to the hospital for worsening dyspnea and increased swelling of the lower extremities.

The diagnosis of follicular lymphoma was originally made 20 years earlier after a needle biopsy of a palpable left groin mass. The patient received six cycles of Rituximab, Cyclophosphamide, Prednisone, Doxorubicin and Vincristine and went into remission for 13 years. He developed relapse of the lymphoma six years ago with a notable left axillary lymph node and was treated with rituximab and bendamustine for six cycles. This was followed by weekly treatment with rituximab but he continued to have progression of disease. He then began a trial of buparlisib (PI3 K inhibitor) and ibrutinib which were discontinued one year later due to an adverse reaction. Further treatment was pursued with trials of Pembrolizumab (anti-programmed death-1 inhibitor) and Etinostat (histone deacetylase inhibitor) followed by lenalidomide and rituximab until early 2020. He achieved complete remission after maintenance therapy with lenalidomide. Of note, the patient acquired asymptomatic coronavirus disease-19 (COVID-19) infection in April 2020 when the pandemic started.

After conditioning with cyclophosphamide, fludarabine, total body irradiation, and horse anti-thymocyte globulin, he underwent an unmodified mismatched unrelated donor peripheral blood stem cell transplant. Pre-transplant workup was negative for donor and recipient cytomegalovirus, Toxoplasma gondii, and Epstein Barr virus serologies and hepatitis panel (Table 2). He was maintained on tacrolimus, sirolimus, and methotrexate for graft-versus-host disease (GVHD) prophylaxis and was planned for Rituximab x 4 cycles post-transplant with the first dose given 3 days prior to this hospital admission. As an outpatient, he was maintained on fluconazole, pentamidine and acyclovir prophylaxis. The post-conditioning course was complicated by diarrhea (Day -3), acute kidney injury (Day -4) and transaminitis (Day -3). The post-transplant course was complicated by hemorrhagic mucositis (Day +6), non-infectious hemorrhagic cystitis (Day +12), febrile...
neutropenia (Day +12) with no infectious etiology identified and ongoing pancytopenia with host engraftment. Repeat bone marrow biopsy showed improving chimerism (host 13%, donor 87%).

On hospital admission (HSCT day 41), he was dyspeptic with increased oxygen requirement and bilateral lower extremity edema. He had an isolated fever of 100.6 °F, worsening acute kidney injury, lactic acidosis, anemia, and thrombocytopenia. He was empirically started on cefepime for antimicrobial coverage.

Blood, urine and sputum cultures, and urinalysis were negative (Tables 1, 3). Chest radiograph showed diffuse bilateral opacities. Computed tomography of the chest revealed new multifocal bilateral ground-glass opacities and consolidations with smooth interlobar septal thickening, superimposed pulmonary edema, and moderate bilateral pleural effusions with bibasal atelectasis (Fig. 1). The electrocardiogram showed normal sinus rhythm. An echocardiogram showed a new decreased ejection fraction of 40%, grade I diastolic dysfunction, mild to moderate global hypokinesis of both ventricles, with borderline pulmonary arterial hypertension, and increased mitral regurgitation. Despite aggressive diagnostic workup and treatment, his condition continued to worsen, ultimately requiring admission to the Intensive Care Unit (ICU) where his course was complicated by atrial fibrillation with rapid ventricular rate and worsening renal function requiring continuous renal replacement therapy. On day 3 of ICU admission, the patient was intubated for worsening respiratory failure and required vasopressor therapy to maintain adequate blood pressure. His antimicrobial coverage was broadened to meropenem and methylprednisolone 0.5 mg/kg IV daily was added due to concerns for hemophagocytic lymphohistiocytosis (HLH). HLH studies revealed fever of 38.1 °C, anemia of 8.4 g/dL, thrombocytopenia of 12,000, elevated ferritin of 5989, fibrinogen 569 and triglycerides 196 (Table 1). Blood cultures showed Pseudomonas fluorescens and coagulase-negative staphylococcus. Despite full supportive measures, he continued to deteriorate and died from multiorgan failure on ICU day 5.

A limited autopsy of the heart was granted by the patient's family. The heart weighed 393 g. There was minimal accumulation of pericardial fluid. The visceral pericardium appeared glistening and edematous. On microscopy, the myocardial interstitium showed edematous change. On higher power examination (200X and 400X magnification) random individual myocardial

### Table 1
Pertinent laboratory parameters during hospitalization.

| Laboratory parameters | Normal Values | Pre-Transplant Labs | Day of Admission (T) | Day of ICU admission (T + 2) | Last Day of Admission (T + 6) |
|-----------------------|---------------|---------------------|----------------------|-----------------------------|-----------------------------|
| Sodium                | 133–143 mEq/L | 140                 | 138                  | 138                         | 136                         |
| Potassium             | 3.3–4.9 mEq/L | 4.5                 | 4.9                  | 4.7                         | 4.7                         |
| Chloride              | 98–108 mEq/L  | 105                 | 102                  | 97                          | 104                         |
| Bicarbonate           | 18–29 mEq/L   | 28                  | 21                   | 27                          | 21                          |
| Blood Urea nitrogen   | 6–20 mg/dL    | 15                  | 37                   | 50                          | 35                          |
| Creatinine            | 0.6–1.3 mg/dL | 1.3                 | 2.9                  | 3.5                         | 2                           |
| Glucose               | 70–140 mg/dL  | 83                  | 122                  | 144                         | 163                         |
| Calcium               | 8.5–10.5 mg/dL| 8.7                 | 8.9                  | 8.5                         | 8.6                         |
| Magnesium             | 1.6–2.6 mg/dL | 1.9                 | 1.7                  | 1.7                         | 2                           |
| Total Protein         | 6.3–8.5 g/dL  | 5.3                 | 5.4                  | 5.6                         | 5                           |
| Albumin               | 3.8–5.0 mg/dL | 3.8                 | 3.8                  | 3.8                         | 2.8                         |
| Aspartate Aminotransferase | < 37 U/L | 21                  | 33                   | 51                          | 947                         |
| Alanine Aminotransferase | < 55 U/L | 17                  | 34                   | 49                          | 464                         |
| Alkaline Phosphatase  | < 130 U/L     | 64                  | 62                   | 70                          | 98                          |
| Total Bilirubin       | < 1.2 mg/dL   | 0.9                 | 0.7                  | 0.7                         | 1                           |
| White Cell Count      | 4.0–11.0 K/mcL| 2.3                 | 7                    | 6.7                         | 3.6                         |
| Red Cell Count        | 3.95–5.54 K/mcL| 3.41           | 2.74                 | 2.63                        | 4.09                        |
| Hemoglobin            | 12.5–16.2 g/dL| 11.6               | 8.4                  | 8.1                         | 12.3                        |
| Hematocrit            | 37.5–49.3 %   | 34.5               | 25.4                 | 24.7                        | 35.4                        |
| Platelets             | 160–400 K/mcL | 107                | 12                   | 31                          | 6                           |
| Neutrophils           | 32.5–74.8%    | 64.7               | 84.1                 | 85.4                        | 98                          |
| Monocytes             | 0.0–12.3 %    | 11.2               | 11.9                 | 11.8                        | 1                           |
| Eosinophils           | 0.0–4.9 %     | 4.3                | 0                    | 0                           | 1                           |
| Basophils             | 0.0–1.5 %     | 1.7                | 0.1                  | 0.1                         | 0                           |
| Lymphocytes           | 12.2–47.4 %   | 18.1               | 2.3                  | 1                           | 0                           |
| Absolute Neutrophil Count | 1.5–7.5 K/mcL | 1.5              | 5.9                  | 5.7                         | 3.5                         |
| Absolute Monocyte Count | 0.0–1.3 K/mcL | 0.3               | 0.8                  | 0.8                         | 0                           |
| Absolute Eosinophil Count | 0.0–0.7 K/mcL | 0.1             | 0                    | 0                           | 0                           |
| Absolute Basophil Count | 0.0–0.2 K/mcL | 0.0              | 0                    | 0                           | 0                           |
| Absolute Lymphocyte Count | 0.9–3.2 K/mcL | 0.4            | 0.1                  | 0.1                         | 0                           |
| Prothrombin time      | 11.1–15.2 sec | 13.2              | 15.1                 | 16.7                        | 20.2                        |
| Activated Partial Thromboplastin Time | 22.5–36.5 sec | 34.8       | 29.5                 | 31.7                        | 36                          |
| INR                   | 0.80–1.20 INR | 1                 | 1.19                 | 1.36                        | 1.73                        |
| BNP                   | 0–100 pg/mL   | –                  | 4596                 | >5000                       | –                           |
| D-Dimer               | < 50 mcg/mL   | –                  | 1.57                 | 2.5                         | –                           |
| Fibrinogen            | 150–400 mg/dL | –                 | –                    | 569                         | 617                         |
| Ferritin              | 22–415 ng/dL  | –                  | 5989                 | 19,361                      | 167,157                     |
| LDH                   | 130–250 U/L   | 161               | 337                  | 1028                        | 3336                        |
| Haptoglobin           | 40–240 mg/dL  | –                  | 104                  | 200                         | 124                         |
| IL-6                  | < 6.0 pg/mL   | 5                  | 272.5                | 3312                        | –                           |
| CRP                   | < 0.30 mg/dL  | 0.2               | 13.67                | 20.98                       | –                           |
| Procalcitonin         | <0.49 ng/mL   | –                  | 0.43                 | 0.6                         | 1.7                         |
| Troponin              | < 0.02 ng/mL  | –                  | 0.32                 | 2.39                        | 36.21                       |
| Lactic Acid           | 0.5–2.6 mm/L  | 1                  | 4.2                  | 2.6                         | 2.6                         |
| Sirolimus level       | mg/mL         | –                  | 9.2                  | 7.8                         | 7.9                         |
| Tacrolimus Level      | mg/mL         | –                  | 10.7                 | 6                           | 7.3                         |
fibers were involved by minute cyst forms of Toxoplasma gondii organisms (Fig. 2A). Several foci showed rupture of the cyst forms with dissemination of the merozoite forms of Toxoplasma (Fig. 2B). There was evidence of destruction of myocardial fibers. The diagnosis of cardiac toxoplasmosis was confirmed by immunostaining (Fig. 2C). The immunostaining was done using Rabbit Polyclonal antibody to Toxoplasma gondii (Cell Marque, 1:200 dilution with Optiview Detection kit on Ventana Benchmark ultra-platform) [4].

Discussion

Toxoplasma gondii in HSCT recipients can cause encephalitis, pneumonitis, cardiac involvement and disseminated infection [1,5,6]. Toxoplasma infection of the myocardium can trigger a local inflammatory response with subsequent myocarditis or cardiomyopathy leading to a life-threatening cardiac event [1,6]. The myocarditis and resulting cardiac dysfunction are commonly associated with involvement of other organs especially the brain and the lungs.

We did not suspect toxoplasmosis as the primary cause for the sudden cardiac dysfunction and heart failure with reduced ejection fraction in our patient at the time of ICU admission. We did not perform serologic polymerase chain reaction (PCR) testing for T. gondii during his brief ICU stay and our patient was not on chemoprophylaxis for Toxoplasma. Diagnosing toxoplasmosis in HSCT recipients is often difficult because of the non-specific signs and symptoms of the infection. Furthermore, pre-transplant donor and recipient serologies for T. gondii were negative. It is likely that the conditioning regimen and immunosuppressive therapy (corticosteroids, tacrolimus, sirolimus) significantly impaired our patient’s immune response, rendering him more susceptible to developing toxoplasmosis. Despite reports of acute toxoplasmosis in recipients who were seronegative for T. gondii, suggesting transmission of infection after HSCT, the source of infection in those cases has not been clearly ascertained as to whether it is due to the transplant procedure by itself or from an environmental source (e.g., ingestion of raw or undercooked meat containing bradyzoites within tissue cysts from infected animals) [7,8].

Toxoplasma PCR serology is a useful tool in defining the patient’s immune status. A combination of reactive IgM with non-reactive IgG antibodies with falloff suggests cardiac Toxoplasma infection [4]. Given the time between the HSCT and hospital admission and risk of acquiring toxoplasmosis in the interim period, it may be important to consider post-transplant serologic testing. The time between HSCT and onset of cardiac symptoms in our patient was 40 days. Case reports have shown a median time of onset to acute infection of 52.5 days [7]. However, HSCT recipients may not be able to reliably mount an IgM response or increase their IgG titers in response to an acute infection and obtaining biopsies in patients who are acutely ill or profoundly thrombocytopenic is difficult [7,9].

Finally, T. gondii detected by histopathology such as in brain or heart tissue is rarely obtained in the antemortem period given the atypical clinical presentation and risks associated with invasive diagnostic methods. Thus, the diagnosis is usually made postmortem, as in our patient. Our case highlights the need for a high level of suspicion for toxoplasmosis in immunocompromised patients presenting with undetermined cause of heart failure post-HSCT.

In patients with acute myocarditis after transplantation, the diagnosis is best made by endomyocardial biopsy, which often demonstrates T. gondii tachyzoites [1]. Histopathological changes include myonecrosis, edema, and an inflammatory cell infiltrate consisting of plasma cells, macrophages, lymphocytes, and eosinophils. The most sensitive technique for the demonstration of tachyzoites in biopsy specimens is the peroxidase-anti-toxoplasma antibody technique or immunostaining [2,4].

Although there are no randomized controlled trials evaluating the efficacy of toxoplasma prophylaxis, universal prophylaxis with trimethoprim-sulfamethoxazole (TMP/SMX) for at least 6 months is recommended for high-risk pre-HSCT toxoplasma-seropositive recipients on the basis of several observational studies [10]. Alternative agents include dapsone-pyrimethamine and leucovorin or atovaquone with or without pyrimethamine and leucovorin; clindamycin and azithromycin when TMP/SMX or pyrimethamine/sulfadiazine cannot be used. Prophylaxis with pyrimethamine 25 mg/day for 6 weeks after HSCT or with TMP/SMX has also been successful in seronegative recipients [1,2].

In HSCT patients, pyrimethamine (25–75 mg/day) and sulfadiazine (4–8 g m/day) with folinic acid (5–10 mg/day) for a minimum of 6 weeks is the treatment of choice [1]. Concerns about the bone marrow suppressive effects of pyrimethamine and sulfadiazine limit their use as empiric therapy [9,11].
In conclusion, we present a unique case of cardiac toxoplasmosis following allogeneic HSCT manifested by acute decompensated heart failure leading to multisystem organ failure and death. Clinicians should have a high clinical suspicion for parasitic causes of heart failure such as toxoplasmosis, perform Toxoplasma PCR serologic testing in blood or other body fluids, and initiate prompt treatment, given the high mortality rate associated with this opportunistic infection in immunocompromised patients.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Informed consent statement**

Informed written consent was obtained from the patient for publication of this report and any accompanying images.
CARE checklist (2013) statement

The authors have read the CARE Checklist (2013), and the manuscript was prepared and revised according to the CARE Checklist (2013).

Declaration of Competing Interest

The authors declare that they do not have any conflict of interest.

Acknowledgements

Akella P, Bhatt I and Serhan M reviewed the literature and contributed to manuscript drafting; Bhatt I performed the microbiological analyses and interpretation and contributed to manuscript drafting; Akella P analyzed and interpreted the imaging findings; Giri D reviewed and assisted with pathological findings and pathology slides; Pastores S was responsible for the revision of the manuscript for important intellectual content; all authors issued final approval for the version to be submitted.

References

[1] Nunes MC, Guimaraes Junior MH, Diamantino AC, Gelape CL, Ferrari TC. Cardiac manifestations of parasitic diseases. Heart 2017;103(9):651–8, doi: http://dx.doi.org/10.1136/heartjnl-2016-309870 Epub 2017/03/13. PubMed PMID: 28285268.

[2] Kirschhoff LV, Weiss LM, Wittner M, Tanowitz HB. Parasitic diseases of the heart. Front Biosci. 2004;9:706–23, doi: http://dx.doi.org/10.2741/1255 Epub 2004/02/10. PubMed PMID: 14766402.

[3] Arribada A, Escobar E. Cardiomyopathies produced by Toxoplasma gondii. Am Heart J 1968;76(3):329–39, doi: http://dx.doi.org/10.1016/0002-8703(68)90227-5 Epub 1968/09/01. PubMed PMID: 4951330.

[4] Foudrinier F, Villena I, Jaussaud R, Aubert D, Chemla C, Martinof F, et al. Clinical value of specific immunoglobulin E detection by enzyme-linked immunosorbent assay in cases of acquired and congenital toxoplasmosis. J Clin Microbiol 2003;41(4):1681–6, doi: http://dx.doi.org/10.1128/jcm.41.4.1681-1686.2003 Epub 2003/04/12. PubMed PMID: 12682160; PubMed Central PMCID: PMCPMC153890.

[5] Chandenier J, Jarry C, Nassif D, Douadi Y, Paris I, Thuillez P, et al. Congestive heart failure and myocarditis after seroconversion for toxoplasmosis in two immunocompetent patients. Eur J Clin Microbiol Infect Dis 2000;19(5):375–9, doi: http://dx.doi.org/10.1038/s1009600050498 Epub 2000/07/18. PubMed PMID: 10898141.

[6] Fricker-Hidalgo H, Brion JP, Durand M, Chavanoz O, Brenier-Pinchart MP, Pelloux H. Disseminated toxoplasmosis with pulmonary involvement after heart transplantation. Transplant Infect Dis 2005;7(1):38–40, doi: http://dx.doi.org/10.1111/j.1399-3062.2005.00086.x Epub 2005/06/30 PubMed PMID: 15984948.

[7] Chan T, Shannon PT, Detsky ME. An unexpected but underestimated case of disseminated toxoplasmosis. Transplant Infect Dis 2013;20(1) doi: ARTN e1281810.1111/tid.12818, PubMed PMID: WOS:000349428000027.

[8] Lopes CS, Silva TL, de Almeida JCN, Costa LVS, Mineo TWF, Mineo JR. Transmission of toxoplasma gondii infection due to bone marrow transplantation: validation by an experimental model. Front Med (Lausanne) 2019;6:227, doi: http://dx.doi.org/10.3389/fmed.2019.00227 Epub 2019/11/05. PubMed PMID: 31681783; PubMed Central PMCID: PMCPMC6804406.

[9] Small TN, Leung L, Stiles J, Kiehn TE, Malak SA, O’Reilly RJ, et al. Disseminated toxoplasmosis following T cell-depleted related and unrelated bone marrow transplantation. Bone Marrow Transpl 2000;25(9):969–73, doi: http://dx.doi.org/10.1038/sj.bmt.1702370 PubMed PMID: WOS:000087057100009.

[10] Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface Bone Marrow Transplant 2009;44(8) 453–5, doi: http://dx.doi.org/10.1038/bmt.2009.254 Epub 2009/10/29. PubMed PMID: 19861977.

[11] Schmidt M, Sonneweil R, Schnell D, Bige N, Hamidfar R, Mongardon N, et al. Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter study. Clin Infect Dis 2013;57(11) 1535–41, doi: http://dx.doi.org/10.1093/cid/cit557 Epub 2013/09/03. PubMed PMID: 23994819.